Testing two doses of a new anemia drug for kidney disease
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests two different doses of pegmolesatide to treat anemia in people with chronic kidney disease who are not on dialysis. It aims to find which dose works better to raise red blood cell levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had chronic kidney disease for at least 6 months and are not on dialysis.
- Your weight is at least 99 pounds (45 kg).
- You have been taking current anemia medicine for 4 to 12 weeks.
- Your hemoglobin level is between 70 and 110 g/L (moderately low).
- You do not have other blood disorders or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting enarodustat (a pill) at different doses can raise red blood cell levels and treat anemia in people with moderate-to-severe chronic kidney disease who are not yet on dialysis.
This trial tests a new medication, pegmolesatide, to treat anemia in people who have been on dialysis for at least three months. It aims to help improve red blood cell levels without needing as many other anemia treatments.
This study tests a new once-monthly injection called pegmolesatide for anemia in people with kidney disease on dialysis who are already taking roxadustat. It aims to see if switching to this injection can keep hemoglobin levels stable and reduce the need for transfusions.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
Hear when a new Renal Anemia in Non-dialysis Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.